CinFina Pharma Announces Initiation of Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of CIN-110 for the Treatment of Obesity

CIN-110 is a potent and highly selective peptide YY (PYY_3-36) analog with an extended half-life designed to significantly reduce nausea and emesis to offer effective long-term weight loss

The MAD study follows the single ascending dose (SAD) study of CIN-110 with data demonstrating safety and tolerability

CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity and metabolic diseases, today announced the initiation of the Phase 1 MAD clinical trial for CIN-110, a novel, highly selective PYY_3-36 analog for the treatment of obesity. This Phase 1 MAD clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CIN-110 in adults with obesity. The initiation of this MAD trial follows the ongoing SAD study, where CIN-110 was well-tolerated with noteworthy reductions in caloric intake and body weight. The SAD study will be used to inform dosing decisions in the current MAD study.

“To date, CIN-110 has demonstrated very strong safety and pharmacokinetic profiles in its single dose study, as well as encouraging pharmacodynamic data,” said Mary Bond, M.S., M.B.A., Chief Translational Science Officer of CinRx Pharma. “We are excited to see this promising asset advance into this next clinical assessment where we will gain an even greater understanding of its potential to provide a safe and effective obesity treatment option for physicians and their patients.”

As a potent and highly selective PYY_3-36 analog with an extended half-life, CIN-110 has the potential to be durable and well-tolerated without the significant nausea and emesis seen in previous attempts to develop PYY-focused therapies. PYY_3-36 is an endogenous hormone secreted from endocrine L-cells in the gut in response to food, particularly fat ingestion, acting as a selective agonist of the neuropeptide Y2 receptor (Y2R) and safely decreasing food intake by reducing appetite.

About CIN-110 Phase 1 MAD Study:

The multiple ascending dose (MAD) study is designed as a randomized, placebo-controlled clinical trial that will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CIN-110 delivered subcutaneously (SC) in study subjects with obesity over 12 weeks. Trial participants are males and females, ages 18-55, with a body mass index between 30.0 and 44.9 kg/m2. The study is planned to include multiple cohorts, each with 12 subjects randomized in a 3:1 ratio to receive SC CIN-110 or a matched placebo, respectively.

About CinFina Pharma:

CinFina Pharma, a CinRx portfolio company, is expanding the treatment options for obesity and its associated comorbidities with a pipeline of therapeutic candidates designed to be safe, tolerable and durable to help people lose weight and keep it off to improve their overall health. CinFina’s four therapeutic candidates are naturally occurring peptides engineered for prolonged activity which send signals in the body to control insulin secretion or feelings of satiety. Learn more at www.CinFina.com.

About CinRx Pharma:

CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients’ quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio.

For more information, please visit www.CinRx.com or follow the company on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730064140/en/